Transgenic overexpression of anti-double-stranded DNA autoantibody and activation of Toll-like receptor 4 in mice induce severe systemic lupus erythematosus syndromes

Journal of Autoimmunity

Volumn 35, Issue 4, 2010, Pages 358-367

  Lee, Tai Ping ^a   Tang, Shye Jye ^c   Wu, Ming Fang ^d   Song, Ying Chyi ^a   Yu, Chia Li ^e   Sun, Kuang Hui ^a,b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI CITY HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN OCEAN UNIVERSITY   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Anti double stranded DNA autoantibody (Anti dsDNA); Lipopolysaccharides (LPS); Single chain variable fragment (scFv); Systemic lupus erythematosus (SLE); Toll like receptor 4 (TLR4)

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; DOUBLE STRANDED DNA ANTIBODY; GAMMA INTERFERON; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; INTERLEUKIN 10; LIPOPOLYSACCHARIDE; TOLL LIKE RECEPTOR 4;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ARTICLE; AUTOIMMUNE DISEASE; BACTERIAL INFECTION; CYTOKINE PRODUCTION; DISEASE SEVERITY; HUMAN; HUMAN CELL; IMMUNE COMPLEX DEPOSITION; IN VITRO STUDY; IN VIVO STUDY; MORBIDITY; MORTALITY; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEINURIA; RECEPTOR UPREGULATION; RISK FACTOR; SPLEEN CELL; SYSTEMIC LUPUS ERYTHEMATOSUS; TRANSGENIC MOUSE; UREA NITROGEN BLOOD LEVEL;

ANIMALS; ANTIBODIES, ANTINUCLEAR; BACTERIAL INFECTIONS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; GENETIC ENGINEERING; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-10; KIDNEY; LIPOPOLYSACCHARIDES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MICE, TRANSGENIC; SINGLE-CHAIN ANTIBODIES; TOLL-LIKE RECEPTOR 4; TRANSGENES;

EID: 77958151180     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2010.07.007     Document Type: Article

References (44)

1. Rahman A., Isenberg D.A. Systemic lupus erythematosus. N Engl J Med 2008, 358:929-939.
2. Mohan C., Morel L., Yang P., Watanabe H., Croker B., Gilkeson G., et al. Genetic dissection of lupus pathogenesis: a recipe for nephrophilic autoantibodies. J Clin Invest 1999, 103:1685-1695.
3. Munoz L.E., Gaipl U.S., Herrmann M. Predictive value of anti-dsDNA autoantibodies: importance of the assay. Autoimmun Rev 2008, 7:594-597.
4. Yung S., Chan T.M. Anti-DNA antibodies in the pathogenesis of lupus nephritis-the emerging mechanisms. Autoimmun Rev 2008, 7:317-321.
5. Waters S.T., McDuffie M., Bagavant H., Deshmukh U.S., Gaskin F., Jiang C., et al. Breaking tolerance to double stranded DNA, nucleosome, and other nuclear antigens is not required for the pathogenesis of lupus glomerulonephritis. J Exp Med 2004, 199:255-264.
6. Bosch X., Guilabert A., Pallares L., Cerveral R., Ramos-Casals M., Bove A., et al. Infections in systemic lupus erythematosus: a prospective and controlled study of 110 patients. Lupus 2006, 15:584-589.
7. Gladman D.D., Hussain F., Ibanez D., Urowitz M.B. The nature and outcome of infection in systemic lupus erythematosus. Lupus 2002, 11:234-239.
8. Cavallo T., Granholm N.A. Bacterial lipopolysaccharide transforms mesangial into proliferative lupus nephritis without interfering with processing of pathogenic immune complexes in NZB/W mice. Am J Pathol 1990, 137:971-978.
9. Granholm N.A., Cavallo T. Bacterial lipopolysaccharide enhances deposition of immune complexes and exacerbates nephritis in BXSB lupus-prone mice. Clin Exp Immunol 1991, 85:270-277.
10. Anders H.J., Schlondorff D. Toll-like receptors: emerging concepts in kidney disease. Curr Opin Nephrol Hypertens 2007, 16:177-183.
11. Liu B., Yang Y., Dai J., Medzhitov R., Freudenberg M.A., Zhang P.L., et al. TLR4 up-regulation at protein or gene level is pathogenic for lupus-like autoimmune disease. J Immunol 2006, 177:6880-6888.
12. Castro J., Balada E., Ordi-Ros J., Vilardell-Tarres M. The complex immunogenetic basis of systemic lupus erythematosus. Autoimmun Rev 2008, 7:345-351.
13. Song Y.C., Sun G.H., Lee T.P., Huang J.C., Yu C.L., Chen C.H., et al. Arginines in the CDR of anti-dsDNA autoantibodies facilitate cell internalization via electrostatic interactions. Eur J Immunol 2008, 38:3178-3190.
14. Sun K.H., Tang S.J., Wang Y.S., Lin W.J., You R.I. Autoantibodies to dsDNA cross-react with the arginine-glycine-rich domain of heterogeneous nuclear ribonucleoprotein A2 (hnRNP A2) and promote methylation of hnRNP A2. Rheumatology 2003, 42:154-161.
15. Luan H.Y., Tang S.J., Yang W., Tsai C.Y., Sun G.H., Sun K.H. Monoclonal anti-double-stranded DNA antibodies cross-react with phosphoglycerate kinase 1 and inhibit the expression and production of IL-2 in activated Jurkat T cell line. Clin Immunol 2006, 120:326-334.
16. Sun K.H., Yu C.L., Tang S.J., Sun G.H. Monoclonal anti-double-stranded DNA autoantibody stimulates the expression and release of IL-1beta, IL-6, IL-8, IL-10 and TNF-alpha from normal human mononuclear cells involving in the lupus pathogenesis. Immunology 2000, 99:352-360.
17. Song Y.C., Tang S.J., Lee T.P., Hung W.C., Lin S.C., Tsai C.Y., et al. Reversing interleukin-2 inhibition mediated by anti-dsDNA autoantibody ameliorates glomerulonephritis in MRL-lpr/lpr mice. Arthritis Rheum 2010, 62:2401-2411.
18. D'Cruz D.P., Khamashta M.A., Hughes G.R. Systemic lupus erythematosus. Lancet 2007, 369:587-596.
19. Rekvig O.P., Nossent J.C. Anti-double-stranded DNA antibodies, nucleosomes, and systemic lupus erythematosus: a time for new paradigms?. Arthritis Rheum 2003, 48:300-312.
20. van Bavel C.C., Fenton K.A., Rekvig O.P., van der Vlag J., Berden J.H. Glomerular targets of nephritogenic autoantibodies in systemic lupus erythematosus. Arthritis Rheum 2008, 58:1892-1899.
21. Yanase K., Smith R.M., Puccetti A., Jarett L., Madaio M.P. Receptor-mediated cellular entry of nuclear localizing anti-DNA antibodies via myosin 1. J Clin Invest 1997, 100:25-31.
22. Seddiki N., Nato F., Lafaye P., Amoura Z., Piette J.C., Mazie J.C. Calreticulin, a potential cell surface receptor involved in cell penetration of anti-DNA antibodies. J Immunol 2001, 166:6423-6429.
23. Fields M.L., Erikson J. The regulation of lupus-associated autoantibodies: immunoglobulin transgenic models. Curr Opin Immunol 2003, 15:709-717.
24. Ohashi P.S., DeFranco A.L. Making and breaking tolerance. Curr Opin Immunol 2002, 14:744-759.
25. Shlomchik M.J., Madaio M.P., Ni D., Trounstein M., Huszar D. The role of B cells in lpr/lpr-induced autoimmunity. J Exp Med 1994, 180:1295-1306.
26. Shlomchik M.J. Sites and stages of autoreactive B cell activation and regulation. Immunity 2008, 28:18-28.
27. Cavallo T., Goldman M., Lambert P.H. Animal model of human disease. Proliferative glomerulonephritis associated with polyclonal B-cell activation. Am J Pathol 1984, 114:346-348.
28. Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol 2006, 6:823-835.
29. Maddison P.J. Autoantibodies in SLE. Disease associations. Adv Exp Med Biol 1999, 455:141-145.
30. Via C.S., Handwerger B.S. T-cell and B-cell function in lupus. Curr Opin Rheumatol 1992, 4:630-634.
31. Handwerger B.S., Rus V., da Silva L., Via C.S. The role of cytokines in the immunopathogenesis of lupus. Springer Semin Immunopathol 1994, 16:153-180.
32. Horwitz D.A., Jacob C.O. The cytokine network in the pathogenesis of systemic lupus erythematosus and possible therapeutic implications. Springer Semin Immunopathol 1994, 16:181-200.
33. Chun H.Y., Chung J.W., Kim H.A., Yun J.M., Jeon J.Y., Ye Y.M., et al. Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus. J Clin Immunol 2007, 27:461-466.
34. Park Y.B., Lee S.K., Kim D.S., Lee J., Lee C.H., Song C.H. Elevated interleukin-10 levels correlated with disease activity in systemic lupus erythematosus. Clin Exp Rheumatol 1998, 16:283-288.
35. Conti P., Kempuraj D., Kandere K., Di G.M., Barbacane R.C., Castellani M.L., et al. IL-10, an inflammatory/inhibitory cytokine, but not always. Immunol Lett 2003, 86:123-129.
36. Llorente L., Richaud-Patin Y., Garcia-Padilla C., Claret E., Jakez-Ocampo J., Cardiel M.H., et al. Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum 2000, 43:1790-1800.
37. Ishida H., Muchamuel T., Sakaguchi S., Andrade S., Menon S., Howard M. Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J Exp Med 1994, 179:305-310.
38. Segal R., Bermas B.L., Dayan M., Kalush F., Shearer G.M., Mozes E. Kinetics of cytokine production in experimental systemic lupus erythematosus: involvement of T helper cell 1/T helper cell 2-type cytokines in disease. J Immunol 1997, 158:3009-3016.
39. Lit L.C., Wong C.K., Li E.K., Tam L.S., Lam C.W., Lo Y.M. Elevated gene expression of Th1/Th2 associated transcription factors is correlated with disease activity in patients with systemic lupus erythematosus. J Rheumatol 2007, 34:89-96.
40. Peng S.L., Moslehi J., Craft J. Roles of interferon-gamma and interleukin-4 in murine lupus. J Clin Invest 1997, 99:1936-1946.
41. Amital H., Govoni M., Maya R., Meroni P.L., Ori B., Shoenfeld Y., et al. Role of infectious agents in systemic rheumatic diseases. Clin Exp Rheumatol 2008, 26:S27-S32.
42. Doria A., Arienti S., Rampudda M., Canova M., Tonon M., Sarzi-Puttini P. Preventive strategies in systemic lupus erythematosus. Autoimmun Rev 2008, 7:192-197.
43. Levesque M.C., St Clair E.W. B cell-directed therapies for autoimmune disease and correlates of disease response and relapse. J Allergy Clin Immunol 2008, 121:13-21.
44. Tieng A.T., Peeva E. B-cell-directed therapies in systemic lupus erythematosus. Semin Arthritis Rheum 2008, 38:218-227.